
Please try another search
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Name | Age | Since | Title |
---|---|---|---|
Patrick Couvreur | - | - | Member of Scientific Advisory Board |
Christian Trepo | - | 2005 | Member of Scientific Advisory Board |
Catherine Bréchignac | 78 | 2011 | Chairman of Scientific Advisory Board |
Jean-Marie Pierre Lehn | 86 | 2005 | Member of Scientific Advisory Board |
Gregory J. Divis | 58 | 2017 | CEO & Director |
Eric J. Ende | 56 | 2018 | Independent Director |
Linda S. Palczuk | 62 | 2018 | Independent Director |
Peter J. Thornton | 60 | 2017 | Independent Director |
Geoffrey M. Glass | 51 | 2018 | Independent Non-Executive Chairman of the Board |
Mark A. McCamish | 72 | 2019 | Independent Director |
Naseem S. Amin | 63 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review